Infliximab is a chimeric monoclonal antibody, belonging to the class of anti-tumor necrosis factor-α (TNF-α) agents, approved for the treatment of psoriasis and psoriatic arthritis. Drugs of this class are known to be associated with an infective risk, probably because they interfere with inflammatory and immune response at different levels. Although cutaneous Staphylococcus aureus infections seem to be more frequent than any other infection in the course of anti-TNF-α treatment, only a few case reports in the literature deal with this side effect, and, in particular, with its management.
De Simone, C., Murri, R., Maiorino, A., Venier, A., Caldarola, G., Management of recurrent cutaneous abscesses during therapy with infliximab, <<CLINICAL THERAPEUTICS>>, 2011; 33 (12): 1993-1996. [doi:10.1016/j.clinthera.2011.10.015] [http://hdl.handle.net/10807/6709]
Management of recurrent cutaneous abscesses during therapy with infliximab
De Simone, Clara;Murri, Rita;Maiorino, Alessia;Venier, Antonio;Caldarola, Giacomo
2011
Abstract
Infliximab is a chimeric monoclonal antibody, belonging to the class of anti-tumor necrosis factor-α (TNF-α) agents, approved for the treatment of psoriasis and psoriatic arthritis. Drugs of this class are known to be associated with an infective risk, probably because they interfere with inflammatory and immune response at different levels. Although cutaneous Staphylococcus aureus infections seem to be more frequent than any other infection in the course of anti-TNF-α treatment, only a few case reports in the literature deal with this side effect, and, in particular, with its management.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
